NASDAQ:BDTX Black Diamond Therapeutics Q4 2025 Earnings Report $1.89 +0.01 (+0.53%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$1.88 -0.01 (-0.74%) As of 10/2/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Black Diamond Therapeutics EPS ResultsActual EPS-$0.14Consensus EPS -$0.18Beat/MissBeat by +$0.04One Year Ago EPSN/ABlack Diamond Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$9.38 millionBeat/MissN/AYoY Revenue GrowthN/ABlack Diamond Therapeutics Announcement DetailsQuarterQ4 2025Date3/16/2026TimeBefore Market OpensConference Call DateMonday, March 16, 2026Conference Call Time7:00AM ETUpcoming EarningsBlack Diamond Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Black Diamond Therapeutics Earnings HeadlinesBlack Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 2, 2026 | globenewswire.comStifel Nicolaus Sticks to Its Buy Rating for Black Diamond Therapeutics (BDTX)August 8, 2026 | theglobeandmail.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 3 at 1:00 AM | Reagan Gold Group (Ad)Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 5, 2026 | globenewswire.comBlack Diamond Therapeutics: Positive Phase 2 Results Offer An UpsideJuly 6, 2026 | seekingalpha.comBlack Diamond Shareholders Approve Directors and Annual Say-on-PayJune 30, 2026 | theglobeandmail.comSee More Black Diamond Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Black Diamond Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Black Diamond Therapeutics and other key companies, straight to your email. Email Address About Black Diamond TherapeuticsBlack Diamond Therapeutics (NASDAQ:BDTX) is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company uses its Mutation-Allostery-Pharmacology (MAP) platform to identify and develop “MasterKey” medicines designed to target families of oncogenic mutations, including alterations that may be difficult to address with conventional therapies. Its research and development programs have included investigational small-molecule therapies directed at cancer-driving pathways such as EGFR and RAF. The company’s drug candidates are being evaluated for potential use in solid tumors, including certain forms of non-small cell lung cancer, glioblastoma and other cancers with specific genomic alterations. Black Diamond Therapeutics was founded in 2014 and is headquartered in the United States. As a development-stage biotechnology company, it has focused primarily on research, clinical trials and advancing its oncology pipeline rather than on marketing approved commercial products. Its programs are intended to serve patients with molecularly defined cancers in markets where the relevant therapies may ultimately be approved.View Black Diamond Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
